DK1080726T3 - Midler til lindring af bivirkninger - Google Patents
Midler til lindring af bivirkningerInfo
- Publication number
- DK1080726T3 DK1080726T3 DK00909678T DK00909678T DK1080726T3 DK 1080726 T3 DK1080726 T3 DK 1080726T3 DK 00909678 T DK00909678 T DK 00909678T DK 00909678 T DK00909678 T DK 00909678T DK 1080726 T3 DK1080726 T3 DK 1080726T3
- Authority
- DK
- Denmark
- Prior art keywords
- side effects
- iminopyrrolidin
- chloro
- methyl
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Inorganic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Amplifiers (AREA)
- Stereophonic System (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP07757999A JP4049477B2 (ja) | 1999-03-23 | 1999-03-23 | 副作用軽減剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1080726T3 true DK1080726T3 (da) | 2006-08-14 |
Family
ID=13637909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00909678T DK1080726T3 (da) | 1999-03-23 | 2000-03-16 | Midler til lindring af bivirkninger |
Country Status (13)
Country | Link |
---|---|
US (2) | US6479500B1 (da) |
EP (1) | EP1080726B1 (da) |
JP (1) | JP4049477B2 (da) |
KR (1) | KR100675044B1 (da) |
CN (1) | CN1144587C (da) |
AT (1) | ATE323494T1 (da) |
AU (1) | AU772486B2 (da) |
CA (1) | CA2331737C (da) |
DE (1) | DE60027369T2 (da) |
DK (1) | DK1080726T3 (da) |
ES (1) | ES2261186T3 (da) |
PT (1) | PT1080726E (da) |
WO (1) | WO2000056337A1 (da) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4110347B2 (ja) * | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗hiv剤 |
PT2368553E (pt) | 2003-04-08 | 2015-03-03 | Progenics Pharm Inc | Formulações farmacêuticas contendo metilnaltrexona |
JP2007519609A (ja) * | 2003-09-17 | 2007-07-19 | アイコス コーポレイション | 細胞増殖を制御するためのchk1インヒビターの使用 |
CN104248763A (zh) | 2005-03-07 | 2014-12-31 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
US7820686B2 (en) | 2006-04-13 | 2010-10-26 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for inflammatory bowel disease |
BRPI0713333A2 (pt) * | 2006-06-30 | 2012-03-06 | Taiho Pharmaceutical Co., Ltd. | Potencializador de terapia de radiação |
EP2139890B1 (en) | 2007-03-29 | 2014-06-25 | Wyeth LLC | Peripheral opioid receptor antagonists and uses thereof |
PE20090700A1 (es) | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
CA2865389A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
TWI429439B (zh) | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
TWI435725B (zh) | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
EP3028743A3 (en) * | 2008-03-05 | 2017-01-25 | Vicus Therapeutics, LLC | Compositions for mucositis and oncology therapies |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
SG10201912293UA (en) * | 2013-06-17 | 2020-02-27 | Taiho Pharmaceutical Co Ltd | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
CN103788075B (zh) * | 2014-02-19 | 2018-03-27 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
CN103980253B (zh) * | 2014-05-06 | 2015-07-08 | 济南百诺医药科技开发有限公司 | 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法 |
CN105859691A (zh) * | 2016-04-07 | 2016-08-17 | 扬子江药业集团南京海陵药业有限公司 | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 |
US11654157B2 (en) | 2017-01-09 | 2023-05-23 | Shuttle Pharmaceuticals, Inc. | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation |
US11730753B2 (en) | 2018-03-03 | 2023-08-22 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744475A (en) * | 1995-03-29 | 1998-04-28 | Taiho Pharmaceutical Co., Ltd. | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
DE69731940T2 (de) * | 1996-09-24 | 2005-05-25 | Taiho Pharmaceutical Co. Ltd. | Uracilderivate enthaltende krebsmetastasen inhibitoren |
-
1999
- 1999-03-23 JP JP07757999A patent/JP4049477B2/ja not_active Expired - Lifetime
-
2000
- 2000-03-16 AT AT00909678T patent/ATE323494T1/de active
- 2000-03-16 KR KR1020007012687A patent/KR100675044B1/ko active IP Right Grant
- 2000-03-16 ES ES00909678T patent/ES2261186T3/es not_active Expired - Lifetime
- 2000-03-16 US US09/701,041 patent/US6479500B1/en not_active Ceased
- 2000-03-16 US US15/684,291 patent/USRE47388E1/en not_active Expired - Lifetime
- 2000-03-16 CN CNB008003939A patent/CN1144587C/zh not_active Expired - Lifetime
- 2000-03-16 DK DK00909678T patent/DK1080726T3/da active
- 2000-03-16 CA CA002331737A patent/CA2331737C/en not_active Expired - Lifetime
- 2000-03-16 AU AU31928/00A patent/AU772486B2/en not_active Expired
- 2000-03-16 EP EP00909678A patent/EP1080726B1/en not_active Expired - Lifetime
- 2000-03-16 WO PCT/JP2000/001607 patent/WO2000056337A1/ja active IP Right Grant
- 2000-03-16 DE DE60027369T patent/DE60027369T2/de not_active Expired - Lifetime
- 2000-03-16 PT PT00909678T patent/PT1080726E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000056337A1 (fr) | 2000-09-28 |
EP1080726A1 (en) | 2001-03-07 |
US6479500B1 (en) | 2002-11-12 |
USRE47388E1 (en) | 2019-05-14 |
EP1080726A4 (en) | 2003-06-25 |
ES2261186T3 (es) | 2006-11-16 |
DE60027369T2 (de) | 2006-09-14 |
CN1144587C (zh) | 2004-04-07 |
KR20010043563A (ko) | 2001-05-25 |
CN1297350A (zh) | 2001-05-30 |
KR100675044B1 (ko) | 2007-01-26 |
CA2331737A1 (en) | 2000-09-28 |
ATE323494T1 (de) | 2006-05-15 |
DE60027369D1 (de) | 2006-05-24 |
PT1080726E (pt) | 2006-07-31 |
AU772486B2 (en) | 2004-04-29 |
JP2000273044A (ja) | 2000-10-03 |
AU3192800A (en) | 2000-10-09 |
CA2331737C (en) | 2008-06-17 |
EP1080726B1 (en) | 2006-04-19 |
JP4049477B2 (ja) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1080726T3 (da) | Midler til lindring af bivirkninger | |
LU92602I2 (fr) | Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci | |
JP2008535902A5 (da) | ||
PL373414A1 (en) | 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands | |
PE20010912A1 (es) | Derivados arilamina y su aplicacion como agentes antitelomerasa | |
JO2503B1 (en) | Benzathiazole derivatives | |
TW200740787A (en) | (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones | |
MXPA04001037A (es) | Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina. | |
DK1646389T3 (da) | Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister | |
NZ525008A (en) | Pyrazole compounds useful as protein kinase inhibitors | |
AU2330202A (en) | Treatment of statin side effects | |
WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
SE9904508D0 (sv) | New compounds | |
MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
MY137156A (en) | Dual nk1/nk3 derivatives | |
WO2008002596A3 (en) | Adenosine a2a receptor antagonists | |
MD2447F2 (en) | Pharmaceutical composition, use thereof and methods of treatment of cephalalgia, migraine, sickness and vomiting | |
EP1839662A4 (en) | ANTITUMOR AGENT | |
PL1841765T3 (pl) | Związek imidazo[4,5-c]pirydyny i sposób leczenia przeciwwirusowego | |
TW200626562A (en) | Crystalline forms of 3-[5-chloro-4-[(2, 4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide | |
GEP20074058B (en) | 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents | |
AR054888A1 (es) | Derivados de quinolina como agentes antibacterianos | |
EA200800154A1 (ru) | Производные хинолина в качестве антибактериальных средств | |
MY151030A (en) | Quinoline derivatives as antibacterial agents | |
WO2003086271A3 (en) | Azole derivatives as antifungal agents |